- -

Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease

RiuNet: Repositorio Institucional de la Universidad Politécnica de Valencia

Compartir/Enviar a

Citas

Estadísticas

  • Estadisticas de Uso

Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease

Mostrar el registro completo del ítem

Hernández Teruel, A.; Pérez-Esteve, É.; González-Álvarez, I.; González-Álvarez, M.; Costero Nieto, AM.; Ferri, D.; Gaviña, P.... (2019). Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease. Molecular Pharmaceutics. 16(6):2418-2429. https://doi.org/10.1021/acs.molpharmaceut.9b00041

Por favor, use este identificador para citar o enlazar este ítem: http://hdl.handle.net/10251/161599

Ficheros en el ítem

Thumbnail
Nombre: MolPharm_Olsalazi ...
Tamaño: 1.151Mb
Formato: PDF
Descripción: Versión del Autor.
Abrir/Preview
[Cerrado]
Nombre: Hernández;Pérez-E ...
Tamaño: 8.996Mb
Formato: PDF
Descripción: Versión editorial
Solicitar una copia al autor

Metadatos del ítem

Título: Double Drug Delivery Using Capped Mesoporous Silica Microparticles for the Effective Treatment of Inflammatory Bowel Disease
Autor: Hernández Teruel, Adrián Pérez-Esteve, Édgar González-Álvarez, Isabel González-Álvarez, Marta Costero Nieto, Ana María Ferri, Daniel Gaviña, Pablo Merino Sanjuán, Virginia Martínez-Máñez, Ramón Sancenón Galarza, Félix
Entidad UPV: Universitat Politècnica de València. Departamento de Química - Departament de Química
Universitat Politècnica de València. Instituto de Reconocimiento Molecular y Desarrollo Tecnológico - Institut de Reconeixement Molecular i Desenvolupament Tecnològic
Universitat Politècnica de València. Departamento de Tecnología de Alimentos - Departament de Tecnologia d'Aliments
Fecha difusión:
Resumen:
[EN] Silica mesoporous microparticles loaded with both rhodamine B fluorophore (S1) or hydrocortisone (S2), and capped with an olsalazine derivative, are prepared and fully characterized. Suspensions of Si and S2 in water ...[+]
Palabras clave: Mesoporous silica microparticles , Gated materials , Smart drug delivery materials , Colon targeted release , Inflammatory bowel disease
Derechos de uso: Reserva de todos los derechos
Fuente:
Molecular Pharmaceutics. (issn: 1543-8384 )
DOI: 10.1021/acs.molpharmaceut.9b00041
Editorial:
American Chemical Society
Versión del editor: https://doi.org/10.1021/acs.molpharmaceut.9b00041
Código del Proyecto:
info:eu-repo/grantAgreement/MINECO//AGL2015-70235-C2-2-R/ES/DESARROLLO DE SISTEMAS HIBRIDOS CON OPTIMIZACION DEL ANCLADO DE BIOMOLECULAS Y DISEÑADOS CON PROPIEDADES DE ENCAPSULACION Y LIBERACION CONTROLADA MEJORADAS/
info:eu-repo/grantAgreement/MINECO//MAT2015-64139-C4-1-R/ES/NANOMATERIALES INTELIGENTES, SONDAS Y DISPOSITIVOS PARA EL DESARROLLO INTEGRADO DE NUEVAS HERRAMIENTAS APLICADAS AL CAMPO BIOMEDICO/
info:eu-repo/grantAgreement/GVA//PROMETEO%2F2018%2F024/ES/Sistemas avanzados de liberación controlada/
Agradecimientos:
We thank the Generalitat Valenciana (Project PROMETE02018/024) and the Spanish Government (Projects AGL2015-70235-C2-2-R and MAT2015-64139-C4-1-R (MINECO/FEDER)) for support. A.H.T. thanks the Spanish MEC for his FPU ...[+]
Tipo: Artículo

References

Baumgart, D. C., & Sandborn, W. J. (2012). Crohn’s disease. The Lancet, 380(9853), 1590-1605. doi:10.1016/s0140-6736(12)60026-9

Pierik, M., Yang, H., Barmada, M. M., Cavanaugh, J. A., Annese, V., Brant, S. R., … Vlietinck, R. (2005). The IBD International Genetics Consortium Provides Further Evidence for Linkage to IBD4 and Shows Gene-Environment Interaction. Inflammatory Bowel Diseases, 11(1), 1-7. doi:10.1097/00054725-200501000-00001

Loftus, E. V. (2004). Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology, 126(6), 1504-1517. doi:10.1053/j.gastro.2004.01.063 [+]
Baumgart, D. C., & Sandborn, W. J. (2012). Crohn’s disease. The Lancet, 380(9853), 1590-1605. doi:10.1016/s0140-6736(12)60026-9

Pierik, M., Yang, H., Barmada, M. M., Cavanaugh, J. A., Annese, V., Brant, S. R., … Vlietinck, R. (2005). The IBD International Genetics Consortium Provides Further Evidence for Linkage to IBD4 and Shows Gene-Environment Interaction. Inflammatory Bowel Diseases, 11(1), 1-7. doi:10.1097/00054725-200501000-00001

Loftus, E. V. (2004). Clinical epidemiology of inflammatory bowel disease: incidence, prevalence, and environmental influences. Gastroenterology, 126(6), 1504-1517. doi:10.1053/j.gastro.2004.01.063

Lupp, C., Robertson, M. L., Wickham, M. E., Sekirov, I., Champion, O. L., Gaynor, E. C., & Finlay, B. B. (2007). Host-Mediated Inflammation Disrupts the Intestinal Microbiota and Promotes the Overgrowth of Enterobacteriaceae. Cell Host & Microbe, 2(2), 119-129. doi:10.1016/j.chom.2007.06.010

Takaishi, H., Matsuki, T., Nakazawa, A., Takada, T., Kado, S., Asahara, T., … Hibi, T. (2008). Imbalance in intestinal microflora constitution could be involved in the pathogenesis of inflammatory bowel disease. International Journal of Medical Microbiology, 298(5-6), 463-472. doi:10.1016/j.ijmm.2007.07.016

Sokol, H., Seksik, P., Furet, J. P., Firmesse, O., Nion-Larmurier, I., Beaugerie, L., … Doré, J. (2009). Low counts of Faecalibacterium prausnitzii in colitis microbiota. Inflammatory Bowel Diseases, 15(8), 1183-1189. doi:10.1002/ibd.20903

Friswell, M., Campbell, B., & Rhodes, J. (2010). The Role of Bacteria in the Pathogenesis of Inflammatory Bowel Disease. Gut and Liver, 4(3), 295-306. doi:10.5009/gnl.2010.4.3.295

Qiu, X., Zhang, M., Yang, X., Hong, N., & Yu, C. (2013). Faecalibacterium prausnitzii upregulates regulatory T cells and anti-inflammatory cytokines in treating TNBS-induced colitis. Journal of Crohn’s and Colitis, 7(11), e558-e568. doi:10.1016/j.crohns.2013.04.002

Yu, C. G., & Huang, Q. (2013). Recent progress on the role of gut microbiota in the pathogenesis of inflammatory bowel disease. Journal of Digestive Diseases, 14(10), 513-517. doi:10.1111/1751-2980.12087

Kappelman, M. D., Rifas–Shiman, S. L., Porter, C. Q., Ollendorf, D. A., Sandler, R. S., Galanko, J. A., & Finkelstein, J. A. (2008). Direct Health Care Costs of Crohn’s Disease and Ulcerative Colitis in US Children and Adults. Gastroenterology, 135(6), 1907-1913. doi:10.1053/j.gastro.2008.09.012

Rocchi, A., Benchimol, E. I., Bernstein, C. N., Bitton, A., Feagan, B., Panaccione, R., … Ghosh, S. (2012). Inflammatory Bowel Disease: A Canadian Burden of Illness Review. Canadian Journal of Gastroenterology, 26(11), 811-817. doi:10.1155/2012/984575

Burisch, J., Jess, T., Martinato, M., & Lakatos, P. L. (2013). The burden of inflammatory bowel disease in Europe. Journal of Crohn’s and Colitis, 7(4), 322-337. doi:10.1016/j.crohns.2013.01.010

Marchetti, M., & Liberato, N. L. (2014). Biological therapies in Crohn’s disease: are they cost-effective? A critical appraisal of model-based analyses. Expert Review of Pharmacoeconomics & Outcomes Research, 14(6), 815-824. doi:10.1586/14737167.2014.957682

Park, S. J. (2014). Clinical characteristics and treatment of inflammatory bowel disease: A comparison of Eastern and Western perspectives. World Journal of Gastroenterology, 20(33), 11525. doi:10.3748/wjg.v20.i33.11525

Ng, S. C., Tang, W., Ching, J. Y., Wong, M., Chow, C. M., Hui, A. J., … Chan, F. K. L. (2013). Incidence and Phenotype of Inflammatory Bowel Disease Based on Results From the Asia-Pacific Crohn’s and Colitis Epidemiology Study. Gastroenterology, 145(1), 158-165.e2. doi:10.1053/j.gastro.2013.04.007

Sood, A. (2003). Incidence and prevalence of ulcerative colitis in Punjab, North India. Gut, 52(11), 1587-1590. doi:10.1136/gut.52.11.1587

Tozun, N., Atug, O., Imeryuz, N., Hamzaoglu, H. O., Tiftikci, A., Parlak, E., … Yurdaydin, C. (2009). Clinical Characteristics of Inflammatory Bowel Disease in Turkey. Journal of Clinical Gastroenterology, 43(1), 51-57. doi:10.1097/mcg.0b013e3181574636

Victoria, C. R., Sassak, L. Y., & Nunes, H. R. de C. (2009). Incidence and prevalence rates of inflammatory bowel diseases, in midwestern of São Paulo State, Brazil. Arquivos de Gastroenterologia, 46(1), 20-25. doi:10.1590/s0004-28032009000100009

Fakhoury, M., Al-Salami, H., Negrulj, R., & Mooranian, A. (2014). Inflammatory bowel disease: clinical aspects and treatments. Journal of Inflammation Research, 113. doi:10.2147/jir.s65979

Mowat, C., Cole, A., Windsor, A., Ahmad, T., Arnott, I., … Driscoll, R. (2011). Guidelines for the management of inflammatory bowel disease in adults. Gut, 60(5), 571-607. doi:10.1136/gut.2010.224154

Di Sario, A., Bendia, E., Schiadà, L., Sassaroli, P., & Benedetti, A. (2016). Biologic Drugs in Crohn’;s Disease and Ulcerative Colitis: Safety Profile. Current Drug Safety, 11(1), 55-61. doi:10.2174/157488631101160212171757

Collnot, E.-M., Ali, H., & Lehr, C.-M. (2012). Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa. Journal of Controlled Release, 161(2), 235-246. doi:10.1016/j.jconrel.2012.01.028

Lamprecht, A., Rodero Torres, H., Schäfer, U., & Lehr, C.-M. (2000). Biodegradable microparticles as a two-drug controlled release formulation: a potential treatment of inflammatory bowel disease. Journal of Controlled Release, 69(3), 445-454. doi:10.1016/s0168-3659(00)00331-x

Teruel, A., Coll, C., Costero, A., Ferri, D., Parra, M., Gaviña, P., … Sancenón, F. (2018). Functional Magnetic Mesoporous Silica Microparticles Capped with an Azo-Derivative: A Promising Colon Drug Delivery Device. Molecules, 23(2), 375. doi:10.3390/molecules23020375

Teruel, A. H., Pérez-Esteve, É., González-Álvarez, I., González-Álvarez, M., Costero, A. M., Ferri, D., … Sancenón, F. (2018). Smart gated magnetic silica mesoporous particles for targeted colon drug delivery: New approaches for inflammatory bowel diseases treatment. Journal of Controlled Release, 281, 58-69. doi:10.1016/j.jconrel.2018.05.007

Sancenón, F., Pascual, L., Oroval, M., Aznar, E., & Martínez-Máñez, R. (2015). Gated Silica Mesoporous Materials in Sensing Applications. ChemistryOpen, 4(4), 418-437. doi:10.1002/open.201500053

Aznar, E., Oroval, M., Pascual, L., Murguía, J. R., Martínez-Máñez, R., & Sancenón, F. (2016). Gated Materials for On-Command Release of Guest Molecules. Chemical Reviews, 116(2), 561-718. doi:10.1021/acs.chemrev.5b00456

Llopis-Lorente, A., Díez, P., Sánchez, A., Marcos, M. D., Sancenón, F., Martínez-Ruiz, P., … Martínez-Máñez, R. (2017). Interactive models of communication at the nanoscale using nanoparticles that talk to one another. Nature Communications, 8(1). doi:10.1038/ncomms15511

De la Torre, C., Domínguez-Berrocal, L., Murguía, J. R., Marcos, M. D., Martínez-Máñez, R., Bravo, J., & Sancenón, F. (2018). ϵ -Polylysine-Capped Mesoporous Silica Nanoparticles as Carrier of the C 9h Peptide to Induce Apoptosis in Cancer Cells. Chemistry - A European Journal, 24(8), 1890-1897. doi:10.1002/chem.201704161

Oroval, M., Díez, P., Aznar, E., Coll, C., Marcos, M. D., Sancenón, F., … Martínez-Máñez, R. (2016). Self-Regulated Glucose-Sensitive Neoglycoenzyme-Capped Mesoporous Silica Nanoparticles for Insulin Delivery. Chemistry - A European Journal, 23(6), 1353-1360. doi:10.1002/chem.201604104

De la Torre, C., Casanova, I., Acosta, G., Coll, C., Moreno, M. J., Albericio, F., … Martínez-Máñez, R. (2014). Gated Mesoporous Silica Nanoparticles Using a Double-Role Circular Peptide for the Controlled and Target-Preferential Release of Doxorubicin in CXCR4-Expresing Lymphoma Cells. Advanced Functional Materials, 25(5), 687-695. doi:10.1002/adfm.201403822

Giménez, C., Climent, E., Aznar, E., Martínez-Máñez, R., Sancenón, F., Marcos, M. D., … Rurack, K. (2014). Towards Chemical Communication between Gated Nanoparticles. Angewandte Chemie International Edition, n/a-n/a. doi:10.1002/anie.201405580

García-Fernández, A., García-Laínez, G., Ferrándiz, M. L., Aznar, E., Sancenón, F., Alcaraz, M. J., … Orzáez, M. (2017). Targeting inflammasome by the inhibition of caspase-1 activity using capped mesoporous silica nanoparticles. Journal of Controlled Release, 248, 60-70. doi:10.1016/j.jconrel.2017.01.002

Llopis-Lorente, A., Lozano-Torres, B., Bernardos, A., Martínez-Máñez, R., & Sancenón, F. (2017). Mesoporous silica materials for controlled delivery based on enzymes. Journal of Materials Chemistry B, 5(17), 3069-3083. doi:10.1039/c7tb00348j

Cabrera, S., El Haskouri, J., Guillem, C., Latorre, J., Beltrán-Porter, A., Beltrán-Porter, D., … Amorós *, P. (2000). Generalised syntheses of ordered mesoporous oxides: the atrane route. Solid State Sciences, 2(4), 405-420. doi:10.1016/s1293-2558(00)00152-7

Lunn, G. (2005). HPLC Methods for Recently Approved Pharmaceuticals. doi:10.1002/0471711683

Navarro, C., González-Álvarez, I., González-Álvarez, M., Manku, M., Merino, V., Casabó, V. G., & Bermejo, M. (2011). Influence of polyunsaturated fatty acids on Cortisol transport through MDCK and MDCK-MDR1 cells as blood–brain barrier in vitro model. European Journal of Pharmaceutical Sciences, 42(3), 290-299. doi:10.1016/j.ejps.2010.12.005

Mura, C., Nácher, A., Merino, V., Merino-Sanjuan, M., Carda, C., Ruiz, A., … Diez-Sales, O. (2011). N-Succinyl-chitosan systems for 5-aminosalicylic acid colon delivery: In vivo study with TNBS-induced colitis model in rats. International Journal of Pharmaceutics. doi:10.1016/j.ijpharm.2011.06.025

Sandborn, W. J., & Hanauer, S. B. (2002). The pharmacokinetic profiles of oral mesalazine formulations and mesalazine pro-drugs used in the management of ulcerative colitis. Alimentary Pharmacology & Therapeutics, 17(1), 29-42. doi:10.1046/j.1365-2036.2003.01408.x

Mladenovska, K., Raicki, R. S., Janevik, E. I., Ristoski, T., Pavlova, M. J., Kavrakovski, Z., … Goracinova, K. (2007). Colon-specific delivery of 5-aminosalicylic acid from chitosan-Ca-alginate microparticles. International Journal of Pharmaceutics, 342(1-2), 124-136. doi:10.1016/j.ijpharm.2007.05.028

Oomen, A. G., Rompelberg, C. J. M., Bruil, M. A., Dobbe, C. J. G., Pereboom, D. P. K. H., & Sips, A. J. A. M. (2003). Development of an In Vitro Digestion Model for Estimating the Bioaccessibility of Soil Contaminants. Archives of Environmental Contamination and Toxicology, 44(3), 281-287. doi:10.1007/s00244-002-1278-0

Versantvoort, C. H. M., Oomen, A. G., Van de Kamp, E., Rompelberg, C. J. M., & Sips, A. J. A. M. (2005). Applicability of an in vitro digestion model in assessing the bioaccessibility of mycotoxins from food. Food and Chemical Toxicology, 43(1), 31-40. doi:10.1016/j.fct.2004.08.007

Tozaki, H., Fujita, T., Komoike, J., Kim, S.-I., Terashima, H., Muranishi, S., … Yamamoto, A. (1999). Colon-specific Delivery of Budesonide with Azopolymer-coated Pellets: Therapeutic Effects of Budesonide with a Novel Dosage Form against 2,4,6-Trinitrobenzenesulphonic Acid-induced Colitis in Rats. Journal of Pharmacy and Pharmacology, 51(3), 257-261. doi:10.1211/0022357991772420

Tozaki, H., Odoriba, T., Okada, N., Fujita, T., Terabe, A., Suzuki, T., … Yamamoto, A. (2002). Chitosan capsules for colon-specific drug delivery: enhanced localization of 5-aminosalicylic acid in the large intestine accelerates healing of TNBS-induced colitis in rats. Journal of Controlled Release, 82(1), 51-61. doi:10.1016/s0168-3659(02)00084-6

Yoo, J.-W., Naeem, M., Cao, J., Choi, M., Kim, W., Moon, H. R., … Jung, Y. (2015). Enhanced therapeutic efficacy of budesonide in experimental colitis with enzyme/pH dual-sensitive polymeric nanoparticles. International Journal of Nanomedicine, 4565. doi:10.2147/ijn.s87816

[-]

recommendations

 

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro completo del ítem